Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Keeping The Body's Repairman From Going Too Far


Developments to Watch

KEEPING THE BODY'S REPAIRMAN FROM GOING TOO FAR

After an injury, the body repairs itself by knitting collagen strands into scar tissue. But sometimes it gets overzealous and makes too much. That can cause pain and disfigurement, immobilize joints, and damage internal organs, including the heart and lungs.

Boston-based Fibro-

med Inc. recently received an exclusive license from Thomas Jefferson University, a Philadelphia medical school, to make a gene-spliced compound for halting scarring. It blocks synthesis of collagen by binding to receptors on the surface of collagen-producing cells. Fibromed hopes to begin animal trials by the end of the year and start human trials in 18 months if it can get Food & Drug Administration approval. The compound might be used after surgery to limit scarring. Fibromed is also working on drugs that stop scarring by inhibiting an enzyme that restructures collagen molecules so that they can form dense layers of scar tissue.EDITED BY PETER COY


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus